FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to cardiology and endocrinology, and can be used for reduction of blood plasma cholesterol concentration. Method involves oral administration of 4.0 g of pea albumin (legumelin) dissolved in 150 ml of water 3 times a day; the course length is 90 days.
EFFECT: use of the invention enables reducing total cholesterol and low-density lipoprotein levels in blood plasma, reducing signs of fatty hepatosis.
1 cl, 3 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF TREATING DIABETES MELLITUS | 2024 |
|
RU2834550C1 |
| METHOD OF TREATING ALZHEIMER'S DISEASE | 2024 |
|
RU2834547C1 |
| METHOD OF TREATING DIABETES MELLITUS IN COMPLEX WITH DALARGIN | 2023 |
|
RU2816021C1 |
| METHOD FOR STEP-BY-STEP MODELING OF NONALCOHOLIC FATTY PANCREATIC DISEASE IN RATS | 2021 |
|
RU2770555C1 |
| METHOD OF TREATING NON-ALCOHOLIC FATTY LIVER DISEASE ACCOMPANYING METABOLIC SYNDROME | 2018 |
|
RU2686042C1 |
| METHOD OF MODELING NON-ALCOHOLIC STEATOHEPATITIS IN RATS | 2009 |
|
RU2394281C1 |
| AGENT FOR METABOLIC SYNDROME CORRECTION | 2011 |
|
RU2458935C1 |
| METHOD FOR VERIFYING CHRONIC HEPATIC PATHOLOGY IN PATIENTS WITH ARTERIAL HYPERTENSION | 2013 |
|
RU2547246C1 |
| METHOD OF LIPID METABOLIC DISORDER CORRECTION | 2007 |
|
RU2337696C1 |
| METHOD OF TREATING NON-ALCOHOLIC LIVER DISEASE ACCOMPANYING TYPE 2 DIABETES MELLITUS | 2013 |
|
RU2538221C1 |
